Abstract
Osteosarcoma (OS) therapy presents numerous challenges, due largely to a low survival rate following metastasis onset. Nerve growth factor (NGF) has been implicated in the metastasis and progression of various cancers; however, the mechanism by which NGF promotes metastasis in osteosarcoma has yet to be elucidated. This study investigated the influence of NGF on the migration and metastasis of osteosarcoma patients (88 cases) as well as the underlying molecular mechanisms, based on RNA-sequencing and gene expression data from a public database (TARGET-OS). In osteosarcoma patients, the expression of NGF was significantly higher than that of other growth factors. This observation was confirmed in bone tissue arrays from 91 osteosarcoma patients, in which the expression levels of NGF and matrix metallopeptidase-2 (MMP-2) protein were significantly higher than in normal bone, and strongly correlated with tumor stage. In summary, NGF is positively correlated with MMP-2 in human osteosarcoma tissue and NGF promotes osteosarcoma cell metastasis by upregulating MMP-2 expression. In cellular experiments using human osteosarcoma cells (143B and MG63), NGF upregulated MMP-2 expression and promoted wound healing, cell migration, and cell invasion. Pre-treatment with MEK and ERK inhibitors or siRNA attenuated the effects of NGF on cell migration and invasion. Stimulation with NGF was shown to promote phosphorylation along the MEK/ERK signaling pathway and decrease the expression of microRNA-92a-1-5p (miR-92a-1-5p). In in vivo experiments involving an orthotopic mouse model, the overexpression of NGF enhanced the effects of NGF on lung metastasis. Note that larotrectinib (a tropomyosin kinase receptor) strongly inhibited the effect of NGF on lung metastasis. In conclusion, it appears that NGF promotes MMP-2-dependent cell migration by inhibiting the effects of miR-92a-1-5p via the MEK/ERK signaling cascade. Larotrectinib emerged as a potential drug for the treatment of NGF-mediated metastasis in osteosarcoma.
Similar content being viewed by others
Introduction
Osteosarcoma (OS) is the most prevalent primary malignant tumor among bone tumors, primarily affecting children and adolescents. Males are more susceptibility to the disease, as indicated by a male-to-female ratio ranging from 1.5 to 2:1 [1]. OS is common to specific sites, including the distal femur (42%), proximal tibia (19%), and proximal humerus (10%) [2]. Recent advances in chemotherapy agents have significantly improved the five-year survival rate for non-metastatic osteosarcoma from 15% to 60% [3]. Nonetheless, the prognosis for patients with metastasis remains poor. Roughly 25% of osteosarcoma patients present with metastasis at the time of diagnosis, and their five-year overall survival rate is below 30% [4]. Conventional chemotherapeutic agents tend to be ineffective against metastatic osteosarcoma, due to its heightened malignancy and propensity for invasion. There is a pressing need to identify new pre-treatment prognostic markers and develop new targeted drugs as adjuvants for chemotherapy.
Using bibliometric and visual methods, Wu et al. presented a comprehensive overview of matrix metalloproteinases (MMPs) in the context of osteosarcoma. Their research addressed the mechanisms by which MMPs promote the invasion and metastasis of osteosarcoma as well as the potential of MMPs as active targets against osteosarcoma. MMPs are a class of zinc- and calcium-dependent proteases that play crucial roles in regulating the expression of cytokines in various cell processes, including inflammation, cell migration, angiogenesis, and apoptosis [5]. Many MMPs have been linked to the progression, invasion and metastasis of various cancers, including osteosarcoma, ovarian cancer, colorectal cancer, breast cancer, and non-small cell lung cancer [5,6,7,8]. MMP overexpression (specifically MMP-2, MMP-9, or MMP-13) is a promising indicator for prognosis and pulmonary metastasis in osteosarcoma [4, 6]. MMP-2 plays a key role in tumor motility and is overexpressed in oral carcinoma, glioblastoma, bladder cancer, bone metastasis, and sarcoma. As for MMPs in the context of osteosarcoma, future research is likely to focus on elucidating the underlying mechanisms, exploring their specific role in osteosarcoma lung metastasis, and investigating their potential as targets for cancer therapy.
MicroRNAs (miRNAs) are endogenous regulatory small non-coding RNAs that recognize complementary sequences in the 3’-untranslated region (UTR) of target genes, resulting in mRNA degradation, translation inhibition, or activation [9]. miRNAs are roughly 22 nucleotides in length. The function post-transcriptionally and play a crucial role in cell proliferation, differentiation, apoptosis, and ontogenesis as well as in modulating gene expression [10]. Numerous studies have explored the strong association between miRNAs and the development of osteosarcoma. For instance, miR-18b-5p, miR-331-3p, and miR-744-5p have shown tumor-suppressive functions involving the growth, proliferation, metastasis, and invasion of osteosarcoma cells [11,12,13]. Previous research has indicated that the EGF-mediated reduction of miR-92a-1-5p regulates HTR-8/SVneo cell invasion through the activation of MAPK8 and FAS, leading to a subsequent increase in MMP-2 and MMP-9 expression [14]. Researchers have also reported the significant downregulation of miR-92a-1-5p expression in the exosomes from prostate cancer patients [15, 16]. Nonetheless, researchers have yet to elucidate the specific effects of miR-92a-1-5p on osteosarcoma cell growth and metastasis, or the underlying mechanism. Further research will be required to confirm the role of miR-92a-1-5p in osteosarcoma and its impact on tumor progression and metastasis.
Tumor cells can induce the growth of sensory and sympathetic nerves within tumor tissue. This often leads to Cancer-Induced Bone Pain (CIBP) [17] in in situ bone tumors and tumor bone metastases, and becomes increasingly difficult to manage as tumor growth progresses [18]. The underlying mechanisms of CIBP encompass various neuropathological processes, including inflammation, ischemia, compression, or injury [19]. Recent studies have reported on the close relationship between CIBP and elevated nerve growth factor (NGF) expression levels [19]. NGF is an important neurotrophic factor promoting the growth of sensory and sympathetic nerves. It is highly expressed in the tumor microenvironment (TME) and interacts with various cells to facilitate cancer progression [20]. Tropomyosin receptor kinase A (TrkA) serves as a high-affinity catalytic receptor for NGF. In its function as a kinase, TrkA orchestrates various NGF effects, including neuronal differentiation, neural proliferation, nociceptor response, the inhibition of programmed cell death, cell metastasis, and tumor progression [20, 21]. Researchers have demonstrated that inhibiting NGF or its receptor (TrkA) significantly retards tumor development, reduces pain-related activity, and ameliorated bone damage in sarcoma. The NGF/TrkA axis has also been implicated in the metastasis of various tumors, including breast cancer [22], lung cancer [23], colon cancer [24], pancreatic cancer [25], and prostate cancer [20]. In recent years, medicinal chemists have made considerable advances in our understanding of TRK inhibitors. Larotrectinib (LOXO-101) is an highly selective small molecule inhibitor of the entire tropomyosin receptor kinase (TRK) family, including TrkA, TrkB, and TrkC. It has received FDA-approval for use in the treatment of TRK fusion-positive cancers, such as colon cancer [26], breast cancer [27], and lung cancer [28]. Despite the important role of the NGF/TrkA axis in tumor metastasis, researchers have yet to identify the specific molecular mechanisms by which it acts on osteosarcoma or the effectiveness of larotrectinib in this context. Further advances in understanding these mechanisms could pave the way for the development of novel targeted therapies for osteosarcoma.
Materials and methods
Analysis of mRNA expression profiles from the Gene Expression Omnibus (GEO) and Genomic Data Commons (GDC)
Gene expression data (GSE16088) were obtained from the GEO database, including comprehensive gene expression profiles from 6 normal tissue samples and 14 human osteosarcoma tumor tissue samples. Transcriptome profiles of osteosarcoma were accessed using the TCGA database via the GDC data portal (https://portal.gdc.cancer.gov/). RNA-Seq analysis was performed on 88 osteosarcoma samples to derive gene expression profiles of the neurotrophin family and tropomyosin receptor kinase (TRK) [29].
Transwell cell migration and invasion assays
Cell migration was examined using 24-well Transwell culture plates (Costar, NY, USA) with pore size of 8-μm. For invasion assays, a 30 μL mixture of Matrigel and 0% DMEM (1:3) was pre-coated onto the filter membrane for 1 h. The osteosarcoma cells were either pre-transfected with siRNAs for 24 h or pretreated with designated inhibitors or the vehicle for 30 min. Approximately 1.5 × 104 cells were seeded into the upper chamber with 200 μL of serum-free medium, while the lower chamber was filled with 300 μL of serum-free DMEM (for migration) and 10% DMEM (for invasion) containing NGF. After incubating in a humidified incubator under 5% CO2 at 37 °C for 18 h, the cells were fixed using 3.7% formaldehyde solution and stained using 0.05% crystal violet. Cell migration and invasion were assessed using a microscope by counting the number of cells that migrated to the lower chamber.
Wound healing assays
Wound healing assays were performed using Ibidi cultures (Ibidi, Munich, Germany) inserted into 12-well plates and left to stand for 1 h. A total of 3 × 104 osteosarcoma cells were inoculated in 100 mL of culture medium on each side of the culture insert. The culture insert was carefully removed after 24 h to create a cell-free area and scratch wound. After washing the sample with PBS, 1 mL of DMEM medium with 0.5% FBS was added. The progression of the scratch wound was observed and photographed using an inverted microscope at 0 and 24 h. The percentage of wound healing was quantified using ImageJ software using the following formula: [wound area (initial) - wound area (final)] / wound area (initial) × 100 [30].
Colony formation assays
Cells were incubated in 6-well plates at a density of 2000 cells per well for 1 week, after which cell colonies were fixed using 4% paraformaldehyde and stained using 0.1% crystal violet solution (Sigma-Aldrich) for 15 min. Finally, the number of positive colonies containing over 50 cells was recorded.
Establishing in vivo orthotopic xenograft model of osteosarcoma with lung metastasis
All animal experiments were conducted in strict adherence to protocols established by the Institutional Animal Care and Use Committee of Shin Kong Wu Ho-Su Memorial Hospital (Taipei, Taiwan) (IACUC approval number 112 SKH006). Male BALB/c nude mice were procured at 4 weeks of age from the Taipei National Laboratory Animal Center. The mice were randomly assigned to three groups: 143B, 143B/NGF, or 143B/NGF+Larotrectinib (n = 5 per group). Under 1.5–2.5% isoflurane anesthesia, 5 × 106 143B or 143B/NGF cells were implanted into the right tibia of each mouse using a solution comprising 50% serum-free DMEM and 50% Matrigel (total volume of 100 μL). The objective was to replicate in situ osteosarcoma growth. The 143B/NGF+Larotrectinib group was administered larotrectinib (50 mg/kg) orally three times a week for five weeks. Body weights and tumor volumes were assessed regularly. Euthanasia was performed via CO2 inhalation at six weeks. Tibia tumor and lung samples were collected, fixed in 10% formalin, and prepared for subsequent analysis [31].
Immunohistochemical (IHC) staining
Human normal bone tissue arrays (BO244g; containing 11 cases of bone tissue and one osteosarcoma case) and human osteosarcoma tissue arrays (OS804d; containing 40 cases of osteosarcoma, and OS802c; containing 50 cases of osteosarcoma) were obtained from US Biomax, Inc (Rockville, MD, USA). The tissue specimens underwent rehydration before immunohistochemical staining using primary antibodies against NGF or MMP-2, which were diluted at a 1:250 ratio. After applying Biotin-labeled secondary antibodies, the antibody binding signal was visualized using the NovoLink Polymer Detection System (Leica Microsystems, Heidelberg, Germany) using 3,3’-diaminobenzidine with hematoxylin for counterstaining. Staining intensity was assessed from three images per slide by three independent pathologists using a scale ranging from 0 to 5 (0: negative, 1: low, 2: weak, 3: moderate, 4: strong, and 5: very strong). IHC scores were calculated by summing the intensity scores. The same procedure was performed on mouse lung tissues for comparative analysis.
Statistical analysis
The data are presented as mean ± standard deviation (SD). Statistical analysis was performed using the two-tailed Student’s t-test to determine the significance of differences between groups, with a significance level set at 0.05.
Details pertaining to materials and cell cultures as well as the procedures and protocols used in cell counting kit-8 (CCK-8) assays, Western blot analysis, quantitative real-time polymerase chain reaction (qRT-PCR) assay, Small interfering RNA (siRNA) transfection, and MicroRNA (miRNA) database searches can be found in the Supplementary Information.
Results
Clinicopathological features and functions of NGF in human osteosarcoma
The NGF/TrkA axis is closely associated with the progression of many cancers and poor clinical outcomes [24, 32]. Analysis was performed on 88 osteosarcoma tissue samples from the Genomic Data Commons (GDC) data portal with the aim of establishing NGF expression levels and elucidating its role in osteosarcoma. In osteosarcoma samples, NGF and TrkA mRNA expression levels were higher than those of BDNF, NT-3, NT-4, TrkB, or TrkC (Fig. 1A, B). The results obtained from commercially available tissue arrays revealed a strong correlation between NGF expression levels and the clinical stage of osteosarcoma (Fig. 1C, D). In our exploration of the impact of NGF on cell motility in osteosarcoma cell lines (143B and MG63), it was observed that NGF treatment led to dose-dependent improvements in wound healing, migration, and invasion abilities (Fig. 1E–J). In summary, the upregulation of NGF in osteosarcoma is positively correlated with the clinical stage of the disease and enhances the metastatic potential.
NGF is positively correlated with MMP-2 in human osteosarcoma tissue and enhances MMP-2-dependent migration of osteosarcoma cells
Numerous studies have confirmed that MMP expression levels are strongly correlated with the poor prognosis after metastasis in osteocarcinoma. They have also established the mechanisms by which MMP promotes osteosarcoma invasion, lung metastasis, and antitumor activity [6, 33]. In the current study, we used the GEO dataset (GSE16088) to analyze the expression of MMPs in normal bone tissues and osteosarcoma tissues. The results revealed that the expression levels of MMP-2, -9, -13, and -14 mRNA are significantly higher in osteosarcoma tissue than in normal bone tissues (Fig. 2A–E). We also examined the impact of NGF on the expression of four MMPs in osteosarcoma cells. NGF induced MMP-2 expression in both osteosarcoma cell lines as well as increases in MMP-2 mRNA and protein levels in a dose-dependent manner (Fig. 2F–I). The functional implications were examined by performing MMP-2 siRNA transfection to reduce the effects of NGF on wound healing and migratory and invasion abilities (Fig. 2J–Q). This analysis revealed that NGF promotes osteosarcoma cell metastasis by upregulating MMP-2 expression. Immunohistochemical (IHC) staining of the osteosarcoma tissue array using MMP-2 antibodies revealed a notable correlation between MMP-2 expression and the clinical stage of the disease (Fig. 2R, S). We also observed a positive correlation between NGF and MMP-2 expression in osteosarcoma tissue (Fig. 2T). These observations suggest that both NGF and MMP-2 are positively correlated with the clinical stage of osteosarcoma and that NGF enhances MMP-2-dependent metastasis of osteosarcoma cells.
MEK/ERK signaling moderates the effects of NGF in promoting MMP-2-mediated wound healing and osteosarcoma cell migration
The MEK/ERK signaling pathway is associated with metastasis in various cancer cell lines, including osteosarcoma [34, 35]. In the current study, we explored the involvement of MEK/ERK signaling in moderating the NGF-induced promotion of MMP-2-mediated wound healing, as well as the migratory and invasion abilities of osteosarcoma cells. This was achieved by using specific inhibitors targeting MEK (PD98059 and U0126) and ERK (ERK inhibitor) as well as MEK and ERK siRNAs. MEK and ERK inhibition significantly attenuated the effects of NGF in promoting MMP-2 mRNA expression and migratory and invasion activity in osteosarcoma cells (Figs. 3A–I, 4A–I).
We determined that NGF stimulation led to MEK and ERK phosphorylation in osteosarcoma cells (Figs. 3J, K, 4J, K). We also determined that MEK inhibitors reversed NGF-mediated ERK phosphorylation (Fig. 4L, M). These findings suggest that MEK/ERK signaling is involved in mediating the effects of NGF on MMP-2-mediated wound healing and cell migration in osteosarcoma cells.
The miR-92a-1-5p/MMP-2 axis regulates NGF-enhanced wound healing and the migration of osteosarcoma cell
Numerous studies have confirmed that miRNAs play key roles in the progression, metastasis, and proliferation of cancer cells. They can also be used as prognostic markers [36, 37]. We initially used two online databases, miRWalk and miRDB, to predict miRNA targets within the 3’-UTR region of MMP-2 mRNA. This analysis revealed 25 candidate miRNAs (Fig. 5A). Treating osteosarcoma cells (143B and MG63) with NGF (100 ng/mL) revealed the significant downregulation of three miRNAs, namely miR-92a-1-5p, miR-4271, and miR-6883-5p (Fig. 5B, C). In both osteosarcoma cell lines, exposure to NGF at various concentrations (30, 50, or 100 ng/mL) revealed the concentration-dependent suppression of miR-92a-1-5p expression (Fig. 5D, E). Transfection of osteosarcoma cells with a miR-92a-1-5p mimic significantly reduced NGF-induced MMP-2 mRNA and protein expression, as well as the cell migration and invasion abilities (Fig. 5F–N). We also investigated the impact of miR-92a-1-5p binding to the MMP-2 3’-UTR on MMP-2 transcription by constructing MMP-2 WT 3’-UTR and MMP-2 MUT 3’-UTR luciferase reporter plasmids (Fig. 5O). NGF was shown to enhance the luciferase activity of the wild-type MMP-2 3’-UTR, whereas the mutant MMP-2 3’-UTR generated no such response (Fig. 5P). Additionally, pre-transfection with a miR-92a-1-5p mimic significantly suppressed the enhancement of MMP-2 luciferase activity induced by NGF (Fig. 5Q). We subsequently investigated the role of MEK and ERK signaling in regulating the NGF-induced repression of miR-92a-1-5p synthesis. Pre-treating osteosarcoma cells with MEK and ERK inhibitors or their respective siRNAs reversed the effects of NGF in repressing miR-92a-1-5p expression (Fig. 5R, S). These findings confirm that in human osteosarcoma cells, miR-92a-1-5p controls MMP-2 expression and cell migration by binding to the 3’-UTR of the MMP-2 gene via the MEK/ERK pathway.
Larotrectinib inhibits NGF-induced metastasis of osteosarcoma cells
The mechanism of endogenous NGF in osteosarcoma was elucidated by establishing an overexpressing NGF osteosarcoma cell line (143B/NGF) to confirm protein expression using Western blot analysis (Fig. 6A–C). The proliferative effects were examined using colony formation assays and cell proliferation experiments. These results revealed no significant difference between 143B and 143B/NGF cells in trms of cell proliferation (Fig. 6D, E). However, in wound healing, transwell migration, and invasion assays, the migration ability of 143B/NGF cells was significantly higher than that of 143B cells, thereby demonstrating that endogenous NGF can control the motility of osteosarcoma cells (Fig. 6F–H). Larotrectinib is an orally administered ATP-competitive inhibitor of the tropomyosin receptor kinase (TRK) family (TRKA, B, and C), which blocks the expression of NGF [26]. We first examined the cytotoxic effects of larotrectinib on 143B/NGF cells. In MTT assays, larotrectinib concentrations of 10, 30, and 100 μM had no effect on cell viability over periods of 24 or 48 h (Fig. 6I). In wound healing, transwell migration, and invasion experiments, larotrectinib significantly inhibited the migration and invasion ability of 143B/NGF cells in a dose-dependent manner (Fig. 6J–O). These results confirm that endogenous NGF can significantly enhance the migration ability of osteosarcoma cells, the effects of which can be suppressed by larotrectinib.
Larotrectinib reverses lung metastasis of osteosarcoma cells in vivo by blocking NGF overexpression
In a previous study, we developed an orthotopic mouse model to explore the mechanisms underlying the lung metastasis of bone cancer [38]. In this study, osteosarcoma cells (143B and 143B/NGF) were orthotopically implanted into the right tibia of mice, after which the body weight and tumor volume was recorded weekly. The tumor volume of the overexpressing NGF cell line (143B/NGF) was significantly larger than that of the original 143B cell line. The oral administration of larotrectinib (50 mg/kg) three times a week significantly inhibited 143B/NGF tumor growth without affecting the body weight of the mice (Fig. 7A, B). Mice were sacrificed 6 weeks after tumor implantation to enable further analysis of tumor volume in the right tibia and the occurrence of lung metastasis. We found that 143B/NGF cells were more likely than 143B cells to grow and undergo lung metastasis. We also determined larotrectinib treatment inhibited both effects (Fig. 7C−G). IHC results of mouse lungs in the 143B/NGF orthotopic model revealed a significantly positive correlation between NGF and MMP-2 protein expression levels (Fig. 7H−K). These results confirm that NGF promotes osteosarcoma metastasis to the lungs of mice. We also analyzed the expression of cancer cells in mouse blood. qPCR results revealed that MMP-2 expression was higher in the 143B/NGF group than in the 143B group. Larotrectinib was shown to inhibit the expression of the MMP-2 gene in the 143B/NGF group, while promoting the expression of miR-92a-1-5p (Fig. 7L, M). These results suggest that NGF promotes osteosarcoma metastasis by promoting MMP-2 expression via the inhibition of miR-92a-1-5p expression. These results also demonstrate that larotrectinib suppresses these effects.
Discussion
Osteosarcoma patients often experience Cancer-induced Bone Pain (CIBP), due to the abundant distribution of sensory nerves in the bones [39]. Studies have confirmed that the secretion of NGF by tumors induces nerve regeneration, while promoting tumor cell survival, cell motility, and invasion [25]. NGF is an important neurotrophic factor shown to promote tumor cell survival, cell motility, and invasion [25]. NGF stimulation leads to the over-activation of the TRKA receptor kinase domain and the activation of downstream signal pathways, including RAS-MAPK, PI3K-AKT, JAK2-STAT3, PLC γ, and Hippo pathway. Note that these pathways are involved in diverse cellular processes, including tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT), perineural invasion (PNI), drug resistance, and cancer pain. Exosomes have been shown to promote the secretion of cytokines (including NGF), thereby fostering the formation of inflammatory and immunosuppressive microenvironments. Exosomes from H1299 have also been shown to affect the corresponding metabolic pathways, thereby facilitating the establishment of a pre-metastatic niche for brain metastases in cases of lung cancer. NGF derived from has been shown to activate the TrkA/ERK/ELK1/ZEB1 signaling pathway in colon cancer cells. This activation boosts the expression of exosomal miR-21-5p, leading to increased proliferation and metastasis. These findings collectively underscore the importance of NGF in tumor metastasis. This study found that NGF induces metastasis in osteosarcoma. We also determined that NGF expression is positively correlated with disease progression. This insight means that NGF could potentially be a therapeutic target in clinical research on osteosarcoma.
Cancer cell lung metastasis is one of the main reasons for the poor prognosis among osteosarcoma patients [33]. Extensive research has implicated MMPs in cancer progression [2]. MMP-2, MMP-7, MMP-9, and MMP-14 have been linked to the progression and metastasis of osteosarcoma [40, 41]. Xu et al. reported that berberine inhibits the migration and invasion of osteosarcoma cells by downregulating the expression of MMP-2 and MMP-9s [42]. Aripiprazole has been shown to inhibit metastatic behavior in human osteosarcoma cells by reducing MMP-2 and MMP-9 expression levels and activity [40]. In cases of esophageal squamous cell carcinoma (ESCC), silencing circ_0046534 has been shown to inhibit the growth and metastasis of ESCC via the miR-339-5p/MMP2 pathway [43]. These studies collectively highlight the crucial role of MMP-2 in tumor metastasis, particularly in cases of osteosarcoma. In the current study, we confirmed that NGF promotes the migration of osteosarcoma cells by mediating the production of MMP-2, rather than other MMPs. We also observed high expression levels of NGF and MMP-2 proteins in late-stage tumor samples in an osteosarcoma tissue array. Note that these expression levels were positively correlated with osteosarcoma progression. These findings suggest a close association between NGF and MMP-2. The current study was based on the hypothesis that MMP-2 is an important factor in the NGF-induced migration of osteosarcoma. Our research identified the targeting of MMP-2 depletion as a novel therapeutic approach to the treatment of osteosarcoma metastasis.
The fact that MEK/ERK signaling pathways are widely involved in cancer progression and metastasis has made them main targets in research on the treatment of osteosarcoma [44, 45]. Lipocalin-2 suppresses osteosarcoma cell metastasis by inhibiting MET expression via the MEK/ERK pathway [46]. By targeting the MEK/ERK signaling pathway, Cobimetinib has been shown to inhibit metastasis in osteosarcoma and enhance the efficacy of doxorubicin in osteosarcoma models. These results confirm the therapeutic value of the MEK/ERK pathway in the clinical management of osteosarcoma [44]. In the current study, NGF promoted the phosphorylation of MEK and ERK, while pharmacological inhibitors and siRNA targeting MEK and ERK inhibited NGF-induced MMP-2 expression and the migration of osteosarcoma cells. The fact that MEK inhibitors also suppress NGF-induced ERK phosphorylation suggests that MEK-dependent ERK activation mediates the NGF-promoted synthesis of MMP-2 and osteosarcoma cell motility. These results suggest that the MEK/ERK signaling pathway plays a critical regulatory role in NGF-induced osteosarcoma metastasis.
MiRNAs are single-stranded RNAs (20-24 nucleotides in length) that lack coding capacity [16, 47]. Their function is to inhibit the translation or degradation of target mRNA, thereby regulating gene expression post-transcriptionally [29]. Previous studies have confirmed that 13 miRNAs in serum are involved in the regulation of osteosarcoma progression, and can be used as diagnostic and prognostic markers [47]. This suggests that miRNA could also be a target for the treatment of osteosarcoma. Despite reports that miR-92a-1-5p disrupts bone homeostasis and promotes bone metastasis in prostate cancer [16], its role in osteosarcoma remains unclear. In the current study, bioinformatics analysis identified MMP-2 as a direct target of miR-92a-1-5p. This study is the first to demonstrate a potential miR-92a-1-5p/MMP-2 regulatory axis involved in metastasis of osteosarcoma. This research also provided evidence that NGF significantly downregulates the expression of miR-92a-1-5p, thereby promoting MMP-2 expression and osteosarcoma metastasis. Treating osteosarcoma cells with MEK and ERK inhibitors or siRNA was shown to reverse the inhibitory effect of NGF on miR-92a-1-5p expression. These findings suggest that NGF enhances MMP-2 expression by suppressing miR-92a-1-5p and promoting osteosarcoma metastasis via the MEK/ERK signaling cascade. Nevertheless, further investigations are warranted to determine whether these signaling cascades modulate the expression of miR-92a-1-5p via transcriptional or post-transcriptional mechanisms.
First-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, are ATP-competitive inhibitors that bind specifically effective in the treatment of various cancers, including infantile fibrosarcoma [48], anaplastic thyroid cancer [49]. Robert et al. demonstrated that inhibiting compensatory neuronal innervation with LOXO-101 (a Trk-NGF inhibitor) further reduced PDAC tumor growth. Our findings provide further evidence that larotrectinib impedes NGF-induced osteosarcoma cell migration in vitro and lung metastasis in vivo. These findings underscore the potential of larotrectinib in attenuating the osteosarcoma cell migration induced by NGF. Further research may unveil novel approaches to the treatment of osteosarcoma.
In summary, this study confirmed that NGF suppresses the synthesis of miR-92a-1-5p via the MEK/ERK signaling cascade, thereby promoting the MMP-2-dependent migration of osteosarcoma cells. Larotrectinib exhibited excellent tumor-targeting effects by inhibiting the NGF-induced growth of tumors and lung metastasis (Fig. 8). Targeting NGF expression is a promising approach to the development of novel treatments for metastatic osteosarcoma.
Data availability
This published article and its supplementary information files include all data generated or analyzed during this study. The data generated in this study are available upon reasonable request from the corresponding author.
References
Li J, Zhang Y, Sun F, Zhang G, Pan XA, Zhou Q. Long noncoding RNA PCGEM1 facilitates tumor growth and metastasis of osteosarcoma by sponging miR-433-3p and targeting OMA1. Orthop Surg. 2023;15:1060–71.
Wu X, Ma S, Wu Z, Zhao Q. Global scientific trends on matrix metalloproteinase and osteosarcoma: a bibliometric and visualized analysis. Front Oncol. 2023;13:1064815.
Wu C, Gong S, Duan Y, Deng C, Kallendrusch S, Berninghausen L, et al. A tumor microenvironment-based prognostic index for osteosarcoma. J Biomed Sci. 2023;30:23.
Gong G, Ganesan K, Xiong Q, Zheng Y. Anti-Invasive and anti-migratory effects of ononin on human osteosarcoma cells by limiting the MMP2/9 and EGFR-Erk1/2 pathway. Cancers. 2023;15:758.
de Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, et al. Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology. Pharm Rev. 2022;74:712–68.
Liu JF, Chen PC, Chang TM, Hou CH. Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma. J Exp Clin cancer Res. 2020;39:254.
Pezeshkian Z, Nobili S, Peyravian N, Shojaee B, Nazari H, Soleimani H, et al. Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer. Cancers. 2021;13:6226.
Othman A, Winogradzki M, Lee L, Tandon M, Blank A, Pratap J. Bone metastatic breast cancer: advances in cell signaling and autophagy related mechanisms. Cancers. 2021;13:4310.
Meade MS. Geographic analysis of disease and care. Annu Rev Public Health. 1986;7:313–35.
Sell MC, Ramlogan-Steel CA, Steel JC, Dhungel BP. MicroRNAs in cancer metastasis: biological and therapeutic implications. Expert Rev Mol Med. 2023;25:e14.
Luo P, Zhang YD, He F, Tong CJ, Liu K, Liu H, et al. HIF-1alpha-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2. Sci Rep. 2022;12:10398.
Zu D, Dong Q, Chen S, Chen Y, Yao J, Zou Y, et al. miRNA-331-3p affects the proliferation, metastasis, and invasion of osteosarcoma through SOCS1/JAK2/STAT3. J Oncol. 2022;2022:6459029.
Liang H, Li L, Zhu S, Tan J, Yang B, Wang X, et al. MicroRNA-744-5p suppresses tumorigenesis and metastasis of osteosarcoma through the p38 mitogen-activated protein kinases pathway by targeting transforming growth factor-beta 1. Bioengineered. 2022;13:12309–25.
Malik A, Pal R, Gupta SK. EGF-mediated reduced miR-92a-1-5p controls HTR-8/SVneo cell invasion through activation of MAPK8 and FAS which in turn increase MMP-2/-9 expression. Sci Rep. 2020;10:12274.
Rodriguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16:156.
Yu L, Sui B, Fan W, Lei L, Zhou L, Yang L, et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. J Extracell Vesicles. 2021;10:e12056.
Yoneda T, Hiasa M, Okui T, Hata K. Cancer-nerve interplay in cancer progression and cancer-induced bone pain. J Bone Min Metab. 2023;41:415–27.
Yang H, Wang Y, Zhen S, Wang B, Jiao M, Liu L, et al. AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation. Acta Biochim Biophys Sin. 2023;55:460–71.
Jing D, Zhao Q, Zhao Y, Lu X, Feng Y, Zhao B, et al. Management of pain in patients with bone metastases. Front Oncol. 2023;13:1156618.
Di Donato M, Giovannelli P, Migliaccio A, Castoria G. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci. 2023;13:60.
Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743–8.
Chang A, Botteri E, Gillis RD, Lofling L, Le CP, Ziegler AI, et al. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci Transl Med. 2023;15:eadf1147.
Ricci A, Salvucci C, Castelli S, Carraturo A, de Vitis C, D’Ascanio M. Adenocarcinomas of the lung and neurotrophin system: a review. Biomedicines. 2022;10:2531.
Han S, Wang D, Huang Y, Zeng Z, Xu P, Xiong H, et al. A reciprocal feedback between colon cancer cells and Schwann cells promotes the proliferation and metastasis of colon cancer. J Exp Clin cancer Res. 2022;41:348.
Peng T, Guo Y, Gan Z, Ling Y, Xiong J, Liang X, et al. Nerve Growth Factor (NGF) encourages the neuroinvasive potential of pancreatic cancer cells by activating the warburg effect and promoting tumor derived exosomal miRNA-21 expression. Oxid Med Cell Longev. 2022;2022:8445093.
Kong W, Zhu H, Zheng S, Yin G, Yu P, Shan Y, et al. Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer. J Cell Mol Med. 2022;26:5539–50.
Liu J, Zhang Y, Zhu Y, Tian L, Tang M, Shen J, et al. Research progress on small molecules inhibitors targeting TRK Kinases. Curr Med Chem. 2023;30:1175–92.
Boulanger MC, Temel JS, Mino-Kenudson M, Ritterhouse LL, Dagogo-Jack I. Primary resistance to Larotrectinib in a patient with squamous NSCLC with subclonal NTRK1 fusion: case report. JTO Clin Res Rep. 2023;4:100501.
Trang NTN, Lai CY, Tsai HC, Huang YL, Liu SC, Tsai CH, et al. Apelin promotes osteosarcoma metastasis by upregulating PLOD2 expression via the Hippo signaling pathway and hsa_circ_0000004/miR-1303 axis. Int J Biol Sci. 2023;19:412–25.
Zhao F, Lang H, Wang Z, Zhang T, Zhang D, Wang R, et al. Human novel MicroRNA Seq-915_x4024 in keratinocytes contributes to skin regeneration by suppressing scar formation. Mol Ther Nucleic Acids. 2019;14:410–23.
Tzeng HE, Lin SL, Thadevoos LA, Lien MY, Yang WH, Ko CY, et al. Nerve growth factor promotes lysyl oxidase-dependent chondrosarcoma cell metastasis by suppressing miR-149-5p synthesis. Cell Death Dis. 2021;12:1101.
Nair RS, Kumar S, Das S, Singh SK, Srivastava P, Sondarva G, et al. TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer. Oncogene. 2023;42:1132–43.
Yuan X, Ma C, Li J, Li J, Yu R, Cai F, et al. Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS. J Bone Oncol. 2023;39:100472.
Chen E, He Y, Jiang J, Yi J, Zou Z, Song Q, et al. CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway. Exp Hematol Oncol. 2023;12:9.
Yeh LT, Lin CW, Lu KH, Hsieh YH, Yeh CB, Yang SF, et al. Niclosamide suppresses migration and invasion of human osteosarcoma cells by repressing TGFBI expression via the ERK signaling pathway. Int J Mol Sci. 2022;23:484.
Zhang P, Zhang J, Quan H, Wang J, Liang Y. MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma. J Orthop Surg Res. 2022;17:236.
Doghish AS, Elballal MS, Elazazy O, Elesawy AE, Shahin RK, Midan HM, et al. miRNAs as potential game-changers in bone diseases: future medicinal and clinical uses. Pathol Res Pract. 2023;245:154440.
Nguyen BT, Lin CY, Chang TK, Fong YC, Thadevoos LA, Lai CY, et al. Melatonin inhibits chondrosarcoma cell proliferation and metastasis by enhancing miR-520f-3p production and suppressing MMP7 expression. J Pineal Res. 2023;75:e12872.
Zarghooni K, Bratke G, Landgraf P, Simon T, Maintz D, Eysel P. The diagnosis and treatment of osteosarcoma and Ewing’s sarcoma in children and adolescents. Dtsch Arztebl Int. (2023).
Alsaeed MA, Ebrahimi S, Alalikhan A, Hashemi SF, Hashemy SI. The potential in vitro inhibitory effects of Neurokinin-1 Receptor (NK-1R) antagonist, aprepitant, in osteosarcoma cell migration and metastasis. Biomed Res Int. 2022;2022:8082608.
Sikora M, Krajewska K, Marcinkowska K, Raciborska A, Wiglusz RJ, Smieszek A. Comparison of selected non-coding RNAs and gene expression profiles between common osteosarcoma cell lines. Cancers. 2022;14:4533.
Xu X, Liu M, Wu H. Berberine inhibits the growth of osteosarcoma through modulating MMP/NM-23 and MAPK/JNK signal pathways. Am J Transl Res. 2023;15:729–44.
Xu T, Hu Y, Zhao Y, Qi Y, Zhang S, Li P. Hsa_circ_0046534 accelerates esophageal squamous cell carcinoma proliferation and metastasis via regulating MMP2 expression by sponging miR-339-5p. Cell Signal. 2023;112:110906.
Ma L, Xu Y, Xu X. Targeted MEK inhibition by cobimetinib enhances doxorubicin’s efficacy in osteosarcoma models. Biochem Biophys Res Commun. 2020;529:622–8.
Hsieh MH, Yang JS, Lin RC, Hsieh YH, Yang SF, Chang HR, et al. Tomatidine represses invasion and migration of human osteosarcoma U2OS and HOS cells by suppression of Presenilin 1 and c-Raf-MEK-ERK Pathway. Molecules. 2020;25:326.
Lu KH, Yang JS, Hsieh YH, Chu HJ, Chou CH, Lu EW, et al. Lipocalin-2 inhibits osteosarcoma cell metastasis by suppressing MET expression via the MEK-ERK pathway. Cancers. 2021;13:3181.
Araki Y, Asano N, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, et al. A validation study for the utility of serum microRNA as a diagnostic and prognostic marker in patients with osteosarcoma. Oncol Lett. 2023;25:222.
Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A. Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer. 2016;63:1468–70.
Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, et al. Molecular features of aggressive thyroid cancer. Front Oncol. 2022;12:1099280.
Acknowledgements
We thank the staff of the Eighth Core Lab, Department of Medical Research, National Taiwan University Hospital for technical support during the study.
Funding
This study was sponsored by grants from the Shin Kong Wu Ho-Su Memorial Hospital (2022SKHBND001), National Taiwan University Hospital (NTUH 109-S4626, NTUH 110-S4949, and NTUH 113-S0073), and National Science and Technology Council (NSTC 112-2314-B-341-005 and NSTC 112-2314-B-002-207).
Author information
Authors and Affiliations
Contributions
CHH designed and performed experiments, analyzed data, and wrote the manuscript. WLC performed and analyzed experiments, and contributed to animal experiments. CYL conceived the project, designed experiments, analyzed data, provided the main funding, and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All animal experiments were conducted following protocols approved by the Institutional Animal Care and Use Committee of the Shin Kong Wu Ho-Su Memorial Hospital (Taipei, Taiwan) (IACUC approval number 112 SKH006).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by Barak Rotblat
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hou, CH., Chen, WL. & Lin, CY. Targeting nerve growth factor-mediated osteosarcoma metastasis: mechanistic insights and therapeutic opportunities using larotrectinib. Cell Death Dis 15, 381 (2024). https://doi.org/10.1038/s41419-024-06752-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-024-06752-0